A roundtable discussion, moderated by Sagar Lonial, MD, FACP, Blood Cancers Today Editor-in-Chief, of the Winship Cancer Institute at Emory University School of Medicine, focused on the latest updates in CAR T-cell therapy for multiple myeloma. Dr. Lonial was joined by Noopur Raje, MD, and Krina Patel, MD, MSc.
Advertisement
Advertisement
The primary endpoints of the phase III ELEVATE-RR study were PFS, AEs, and events of clinical interest.
Reseserchers with the German CLL Study Group conducted a prospective analysis of karyotype complexity in patients with CLL.
Patients with mutated IGHV had a median PFS of 14.6 years compared with 4.2 years in patients with unmutated IGHV.
Japan's MHLW grants orphan drug designation to treatments designed for fewer than 50,000 patients.
Karun Neupane, MD, discusses why the meeting was a valuable experience for him as a first-time attendee.
The study was conducted because it was “uncertain whether a fractionated schedule provides additional benefit."
Researchers analyzed prognostic impact of NPM1 MRD in a real-world cohort of patients with NPM1-mutated AML.
The primary endpoints were short-term event-free survival and overall survival in the intention-to-treat population.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
Expert Interviews
Blood Cancers Today delivers the latest news, education, and information relevant to hematologic oncology patients and practices.
Sign up to receive Blood Cancers Today eNewsletters:
Knowledge Hubs
Trending on MashupMD
American Society of Clinical Oncology
American Society of Hematology
Baseline PET radiomics outperforms the IPI risk score for prediction of outcome in diffuse large
Blood Journal
Blood JournalBaseline PET radiomics outperform the IPI risk score
#PET
#DLBCL
Houston Chronicle
A Houston doctor’s work transformed leukemia treatment. Next up: Helping patients avoid chemotherapy
MD Anderson Cancer Center
MD Anderson Cancer CenterDespite dramatic advances in leukemia pioneered
#Leukemia
#EndCancer
academy.hematology.org
